Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
5.37 (1y: -24%)
Market Cap 177.7 M P/E(ttm)
Enterprise Value 175.68 M P/B
NYMX- NAS (USA)
Nymox Pharmaceutical Corporation
  • Currently 1/5
Business Predictability Rank: 1-Star
Back Testing Results:
Average gain of all 1-Star stocks: 1.1% per year.
% of Stocks that are in still loss if held for 10yrs: 45%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$5.37
Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry		 vs
history
Cash to Debt No Debt
NYMX's Cash to Debt is ranked higher than
80% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 3.50 vs. NYMX: No Debt )
NYMX' s 10-Year Cash to Debt Range
Min: 0.28   Max: No Debt
Current: No Debt
Equity to Asset -4.473
NYMX's Equity to Asset is ranked lower than
63% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.53 vs. NYMX: -4.473 )
NYMX' s 10-Year Equity to Asset Range
Min: -4.47   Max: 0.72
Current: -4.47
-4.47
0.72
F-Score: 2
Z-Score: -45.71
M-Score: -0.84
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry		 vs
history
Operating margin (%) -247.20
NYMX's Operating margin (%) is ranked higher than
50% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. NYMX: -247.20 )
NYMX' s 10-Year Operating margin (%) Range
Min: -2217   Max: -247.2
Current: -247.2
-2217
-247.2
Net-margin (%) -248.2
NYMX's Net-margin (%) is ranked higher than
50% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: -4.20 vs. NYMX: -248.2 )
NYMX' s 10-Year Net-margin (%) Range
Min: -2182   Max: -248.2
Current: -248.2
-2182
-248.2
ROA (%) -434.9
NYMX's ROA (%) is ranked lower than
62% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: -2.40 vs. NYMX: -434.9 )
NYMX' s 10-Year ROA (%) Range
Min: -470.6   Max: -51.5
Current: -434.9
-470.6
-51.5
Revenue Growth (%) 73.2
NYMX's Revenue Growth (%) is ranked higher than
99% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. NYMX: 73.2 )
NYMX' s 10-Year Revenue Growth (%) Range
Min: -15.9   Max: 77.8
Current: 73.2
-15.9
77.8
EBITDA Growth (%) 9.5
NYMX's EBITDA Growth (%) is ranked higher than
92% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. NYMX: 9.5 )
NYMX' s 10-Year EBITDA Growth (%) Range
Min: -5.1   Max: 20
Current: 9.5
-5.1
20
EPS Growth (%) 7.8
NYMX's EPS Growth (%) is ranked higher than
92% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. NYMX: 7.8 )
NYMX' s 10-Year EPS Growth (%) Range
Min: -3.1   Max: 18.9
Current: 7.8
-3.1
18.9
» NYMX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2011

NYMX Guru Trades in Q2 2011

Jim Simons 14,600 sh (New)
» More
Q3 2011

NYMX Guru Trades in Q3 2011

Jim Simons Sold Out
» More
Q2 2012

NYMX Guru Trades in Q2 2012

George Soros 38,400 sh (New)
» More
Q3 2012

NYMX Guru Trades in Q3 2012

George Soros Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with NYMX

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2012-09-30 Sold Out 0.0036%$5.9 - $6.88 $ 5.37-15%0
George Soros 2012-06-30 New Buy$6.5 - $8.39 $ 5.37-29%38400
Premium More recent guru trades are included for Premium Members only!!
» Financial Charts

Peter Lynch Chart

Ratios

vs
industry		 vs
history
P/S 56.40
NYMX's P/S is ranked lower than
53% of the 677 Companies
in the Global Biotechnology industry.

( Industry Median: 7.38 vs. NYMX: 56.40 )
NYMX' s 10-Year P/S Range
Min: 56   Max: 729
Current: 56.4
56
729
EV-to-EBIT 12.8
NYMX's EV-to-EBIT is ranked lower than
51% of the 244 Companies
in the Global Biotechnology industry.

( Industry Median: 22.58 vs. NYMX: 12.8 )
NYMX' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: 12.8

Valuation & Return

vs
industry		 vs
history
Price/Net Current Asset Value 537
NYMX's Price/Net Current Asset Value is ranked lower than
57% of the 502 Companies
in the Global Biotechnology industry.

( Industry Median: 45.80 vs. NYMX: 537 )
NYMX' s 10-Year Price/Net Current Asset Value Range
Min: 456   Max: 686
Current: 537
456
686
Price/Median PS Value 0.2
NYMX's Price/Median PS Value is ranked higher than
96% of the 550 Companies
in the Global Biotechnology industry.

( Industry Median: 1.00 vs. NYMX: 0.2 )
NYMX' s 10-Year Price/Median PS Value Range
Min: 0.3   Max: 1.6
Current: 0.2
0.3
1.6
Forward Rate of Return (Yacktman) 14.47
NYMX's Forward Rate of Return (Yacktman) is ranked higher than
96% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. NYMX: 14.47 )
NYMX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -10.2   Max: 45
Current: 14.47
-10.2
45

Business Description

Nymox Pharmaceutical Corporation was incorporated under the Canada Business Corporations Act in May, 1995. The Company has two subsidiaries: one wholly-owned subsidiary named Nymox Corporation and the other a majority owned subsidiary named Serex, Inc., acquired in 2000. Nymox Corporation conducts some research and development, while Serex conducts research and development, and some of the manufacturing for NicAlert and TobacAlert. It is a biopharmaceutical Corporation with three proprietary products on the market, and a significant R&D pipeline of products in development for the treatment of such conditions and diseases as enlarged prostate (benign prostatic hyperplasia or BPH), Alzheimer's disease (AD), E. coli O157:H7 contamination of food and drink products, and bacterial infections and for the diagnosis of AD and other indications. Nymox has also U.S. and global patent rights for the use of statin drugs for the treatment and prevention of Alzheimer's disease. Nymox has developed and markets NicAlert and TobacAlert, which are inexpensive, simple-to-use test strips for determining whether a person is using tobacco products (NicAlert) or has been recently exposed to second-hand smoke (TobacAlert). Both NicAlert and TobacAlert employ Serex, Inc.'s patented technology to provide an accurate read-out of levels of cotinine, a by-product of the body's breakdown of nicotine and generally regarded as the indicator of tobacco exposure for smokers and nonsmokers. NicAlert received clearance from the U.S. Food and Drug Administration (FDA) in October 2002 for medical use to determine if an individual has been exposed to tobacco products. In January, 2006, the company announced the certification of the urine-based version of NicAlert with a CE Mark making it eligible for sale in the European Union and in May, 2006 the certification of the saliva-based version of NicAlert with a CE Mark. In September, 2003, it launched TobacAlert for nonmedical testing for second hand smoke exposure in the U.S. It markets the NicAlert and TobacAlert tests through its own marketing arm and distributors in North America, Europe and Asia. NicAlert and TobacAlert products are currently partly manufactured through out-sourcing arrangements with contract manufacturers. The Company offers AlzheimAlert, a proprietary urine assay that could aid physicians in the diagnosis of Alzheimer's disease. It offers a kit version of the AlzheimAlert assay for sale in Europe. The company is developing treatments for enlarged prostate, using novel compounds. Its candidate NX-1207, which successfully completed a multi-center, double-blind, placebo-controlled Phase 2 trials in September 2006, is presently in Phase 3. The company is developing novel antibacterial agents for the treatment of E. coli O157:H7 bacterial contamination in hamburger meat and other food and drink products and for the treatment of urinary tract and other bacterial infections in humans which have proved hig
Company Website
Industry: Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG
» More Articles for NAS:NYMX

Headlines

Articles On GuruFocus.com
No related article found.

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK